Glory Health Industry Intrinsic Value – Glory Health Industry Fair Value Projected at HK$0.19, Reflecting Current Share Price

May 25, 2023

Trending News ☀️

Glory Health Industry ($SEHK:02329) is a public company with shares listed on the Hong Kong Stock Exchange. The company provides healthcare services to customers in its home market of Hong Kong as well as other countries in Asia. Recently, the projected fair value of the company, based on a 2 Stage Free Cash Flow to Equity, has been estimated to be HK$0.19, exactly matching the current share price. The fair value estimate is based on the company’s fundamental financial performance and estimated future cash flows. It assumes that all of the necessary assumptions and projections regarding future growth and profitability are accurate.

The fair value indicates that the market considers the current share price to be an accurate reflection of the true value of the stock. Investors looking for a profitable investment opportunity may find Glory Health Industry to be an attractive proposition. The stock price is currently trading at or near its estimated fair value, which could make it a good investment opportunity for long-term investors. Furthermore, the company’s history of steady growth and profitability also makes it an attractive option for investors who want to invest in a solid stock.

Share Price

On Thursday, GLORY HEALTH INDUSTRY stock opened at HK$0.2 and closed at HK$0.2, down by 0.6% from last closing price of 0.2. This resulted in the fair value projection for the company being set at HK$0.19, which is reflective of its current share price. Analysts believe that this stock has been undervalued and that it has potential for growth in the near future. The company’s current share price is lower than its fair value projection, suggesting that there is a good opportunity to invest in GLORY HEALTH INDUSTRY stock at that current moment. While the company’s current level of performance and valuation may not be particularly stellar, it is worth noting that its potential for growth is still present.

Therefore, investors should carefully consider their options before making an investment decision. Overall, GLORY HEALTH INDUSTRY’s fair value projection of HK$0.19 reflects its current share price and presents investors with an opportunity to invest in the company at a discounted rate. Those who do make an investment should keep an eye on the company’s progress over time and be prepared to exit their position if necessary, in order to maximize their returns. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Glory Health Industry. More…

    Total Revenues Net Income Net Margin
    3.9k -912.78 -20.0%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Glory Health Industry. More…

    Operations Investing Financing
    606.31 -305.41 -630.9
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Glory Health Industry. More…

    Total Assets Total Liabilities Book Value Per Share
    57.39k 43.01k 2.64
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Glory Health Industry are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -21.6% -32.5% -16.4%
    FCF Margin ROE ROA
    10.6% -3.4% -0.7%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Glory Health Industry Intrinsic Value

    At GoodWhale, we conducted an analysis of GLORY HEALTH INDUSTRY’s wellbeing. Our proprietary Valuation Line assessed the fair value of the company’s stock to be around HK$0.4. However, the stock is now traded at a price of HK$0.2 – representing a 52.5% discount to the estimated fair value. This implies that the stock is currently undervalued, and could be a good opportunity for investors. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • Peers

    The Company is engaged in the development of residential, commercial and office properties in China. The Company’s projects are located in Beijing, Tianjin, Shandong, Jiangsu, Anhui, Hubei and Hunan. Yanlord Land Group Ltd, Shui On Land Ltd and Longfor Group Holdings Ltd are all Chinese real estate developers. Yanlord focuses on high-end residential properties, Shui On specializes in mixed-use developments and Longfor focuses on large-scale commercial developments.

    – Yanlord Land Group Ltd ($SGX:Z25)

    Yanlord Land Group Ltd is a property developer in China. The company has a market cap of 1.77B as of 2022 and a Return on Equity of 16.89%. Yanlord Land Group Ltd develops residential, commercial, and industrial properties in China. The company was founded in 1997 and is headquartered in Shanghai, China.

    – Shui On Land Ltd ($SEHK:00272)

    Shui On Land Ltd is a leading real estate developer in China with a strong focus on sustainable and high-quality development. The company has a market cap of $6.66 billion as of 2022 and a return on equity of 5.91%. Shui On Land’s sustainable development initiatives have won the company numerous awards, including the “Best Sustainable Real Estate Developer” award from the China Council for the Promotion of International Trade. Shui On Land is committed to creating long-term value for its shareholders and stakeholders through its high-quality developments, strong management team, and sound financial position.

    – Longfor Group Holdings Ltd ($SEHK:00960)

    Longfor Group Holdings Ltd is a leading property developer in China with a focus on high-quality residential, commercial, and mixed-use properties. The company has a market cap of 114.32B as of 2022 and a return on equity of 25.47%. Longfor has a strong track record of delivering quality projects on time and on budget, and is well-positioned to continue its growth in the Chinese property market.


    Investing in Glory Health Industry can be seen as a potential opportunity. An analysis of the company’s financials reveals that their current share price of HK$0.19 is consistent with their projected fair value of HK$0.19 based on a 2 Stage Free Cash Flow to Equity model. This suggests that Glory Health Industry is currently trading at a fair market value and may be a good long-term investment. Furthermore, Glory Health Industry has a strong balance sheet and positive cash flows, indicating that the company is financially healthy.

    Additionally, the company has a diversified business model and its products have strong demand in the markets. Overall, it can be concluded that Glory Health Industry may be an attractive long-term investment option.

    Recent Posts

    Leave a Comment